Looking to address medical needs and reducing development and preparedness costs for US taxpayers, the Biomedical Advanced Research and Development Authority recently purchased and began accepting Paratek Pharmaceuticals’ NUZRYA antibiotic used to treat anthrax infections. Using the authorities and funding of Project BioShield, BARDA awarded Paratek the contract as early as 2019, potentially totalling up to $285 Million over a span of 10 years for the development of anthrax post-exposure drugs and their regulatory approval.
Read more about this news here.
